How should unfractionated heparin be administered and monitored for anticoagulation during cardiovascular surgery requiring cardiopulmonary bypass?

Heparin Administration and Monitoring During Cardiovascular Surgery

For cardiovascular surgery requiring cardiopulmonary bypass (CPB), administer an initial heparin bolus of 300-400 U/kg (with 300 U/kg for procedures <60 minutes and 400 U/kg for procedures >60 minutes), target an activated clotting time (ACT) of ≥480 seconds before initiating CPB, and monitor ACT at regular intervals throughout the procedure with additional heparin doses as needed to maintain this target. 1

Initial Heparin Dosing

The FDA-approved dosing for cardiovascular surgery specifies:

• Minimum initial dose: 150 U/kg 1
• Standard dosing: 300 U/kg for procedures estimated to last <60 minutes 1
• Extended procedures: 400 U/kg for procedures estimated to last >60 minutes 1

The 2024 EACTS/EACTAIC/EBCP guidelines recommend individualized heparin management to reduce postoperative coagulation abnormalities and bleeding complications (Class IIa, Level B). 2

Target ACT and Monitoring

Target ACT threshold: ≥480 seconds before initiating CPB 3

This represents the most extensively reported and standardized target in the cardiac surgery literature. 3 The International Society on Thrombosis and Haemostasis (ISTH) consensus defines heparin resistance as the inability to achieve ACT ≥480 seconds after 500 U/kg. 3

Monitoring Protocol

• Perform ACT checks at regular intervals based on institutional protocols (Class I, Level C) 2
• Baseline measurement: Check ACT, aPTT, INR, and platelet count before heparin administration 1
• During CPB: Monitor ACT approximately every 30 minutes during bypass 4
• Administer supplemental heparin if ACT falls below target 2, 1

Managing Heparin Resistance

If target ACT is not achieved after initial dosing:

1. Administer additional heparin boluses to reach ACT ≥480 seconds 2, 3
2. Consider fresh frozen plasma or antithrombin concentrate if resistance persists after 500 U/kg total dose 3
3. Verify ACT measurement accuracy - different devices (Hemochron vs. i-STAT) can yield systematically different values 5

Common pitfall: The definition of heparin resistance varies widely in practice. Using the standardized threshold of failure to achieve ACT ≥480 seconds after 500 U/kg provides consistency. 3

Alternative Anticoagulation

For patients with heparin-induced thrombocytopenia (HIT) Type 2:

• Bivalirudin should be considered as first-line anticoagulation (Class IIa, Level B) 2
• Argatroban may be considered in patients with significant renal dysfunction (Class IIb, Level C) 2

Protamine Reversal

After CPB completion:

• Use protamine-to-heparin ratio <1.0 to avoid protamine overdosing (Class I, Level B) 2
• Discontinue cardiotomy suction when starting protamine administration (Class IIa, Level C) 2
• Calculate protamine dose based on circulating heparin level derived from the dose-response curve 6

Additional Safety Measures

• Monitor platelet counts, hematocrit, and occult blood throughout heparin therapy regardless of administration route 1
• Optimize CPB systems following a minimally invasive extracorporeal circulation (MiECC)-like approach to reduce blood loss and haemodilution (Class I, Level B) 2
• Minimize priming volumes and use autologous priming as part of blood conservation strategy (Class I, Level A) 2

Critical safety warning: Fatal medication errors have occurred when concentrated heparin vials (10,000 units/mL) were confused with catheter lock flush products. Carefully verify vial concentration before administration. 1